Novocure to Report Fourth Quarter, Year-End Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a conference call and webcast to discuss its fourth quarter and full-year 2015 financial results at 5 p.m. EST on Feb. 29, 2016.
Schedule for press release and conference call:
- Q4 and year-end press release: After market close on Feb. 29, 2016
- Q4 and year-end conference call/webcast: 5 p.m. EST on Feb. 29, 2016
- Domestic dial-in number: (877) 726-5929
- International dial-in number: (530) 379-4648
- Conference ID: 39664845
Access the webcast live from the Investor Relations page of Novocure.com. A replay of the discussion will be available on our website for at least 14 days following the call.
Novocure is a Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s U.S. operations are based in Portsmouth, New Hampshire, and New York City. Additionally, the company has offices in Germany, Switzerland, and Japan and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Quarterly Report on Form 10-Q filed on Oct. 27, 2015, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Media and Investor Contact:
Ashley Cordova, 212-767-7558